CD8A and neoplasm: Among the possible immunological approaches, attempts have been made to use peptide vaccines targeted mainly at the stimulation of tumor-specific MHC class I-restricted CD8+ cytotoxic T lymphocytes (CTLs), which are important terminal effectors of anti-tumor immunity (14).